Phaseline

Targets › SLC7A1

SLC7A1 (High affinity cationic amino acid transporter 1): drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

High-affinity, low capacity permease involved in the transport of the cationic amino acids (arginine, lysine and ornithine) in non-hepatic tissues. (UniProt, P30825)

Open in Phaseline: the race on SLC7A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
China Medical University HospitalB10 L-BPA Injection
Boron-10 enriched L-para-boronophenylalanine (L-BPA); a boron delivery agent for boron neu
SLC7A1Phase 2Head and Neck Cancer; Malignant Brain TumorsDec 2026

Conditions

Head and Neck Cancer (1) Malignant Brain Tumors (1)

Modalities

small molecule (1)

Companies

China Medical University Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.